ArticleNature protocols2014
Chemical ablation of tumor-initiating human pluripotent stem cells.
Article in Nature protocols, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed.
- Elimination of tumorigenic pluripotent stem cells from their differentiated cell therapy products: An important step toward ensuring safe cell therapy.Stem cell reports · 2025Review
- Label-Free and High-Throughput Removal of Residual Undifferentiated Cells From iPSC-Derived Spinal Cord Progenitor Cells.Stem cells translational medicine · 2024Article
- Research progress of autoimmune diseases based on induced pluripotent stem cells.Frontiers in immunology · 2024Review
- Innovations in Stem Cell Therapy for Diabetic Wound Healing.Advances in wound care · 2023Review
- Optimizing Generation of Stem Cell-Derived Islet Cells.Stem cell reviews and reports · 2022Review
- The Tumorigenic Potential of Human Pluripotent Stem Cells.Stem cells translational medicine · 2022Article
- Xeno-Free Integrated Platform for Robust Production of Cardiomyocyte Sheets from hiPSCs.Stem cells international · 2022Article
- The Impact of Acquired Genetic Abnormalities on the Clinical Translation of Human Pluripotent Stem Cells.Cells · 2021Review
- Cell surface markers for immunophenotyping human pluripotent stem cell-derived cardiomyocytes.Pflugers Archiv : European journal of physiology · 2021Review
- Cell-Based Therapeutic Approaches for Cystic Fibrosis.International journal of molecular sciences · 2020Review
- Prevention of tumor risk associated with the reprogramming of human pluripotent stem cells.Journal of experimental & clinical cancer research : CR · 2020Review
- Elimination of Teratogenic Human Induced Pluripotent Stem Cells by Bee Venom via Calcium-Calpain Pathway.International journal of molecular sciences · 2020Article
- Report of the Key Opinion Leaders Meeting on Stem Cell-derived Beta Cells.Transplantation · 2018Review
- Atorvastatin Inhibits the HIF1α-PPAR Axis, Which Is Essential for Maintaining the Function of Human Induced Pluripotent Stem Cells.Molecular therapy : the journal of the American Society of Gene Therapy · 2018Article
- Elimination of undifferentiated human embryonic stem cells by cardiac glycosides.Scientific reports · 2017Article
- Technical approaches to induce selective cell death of pluripotent stem cells.Cellular and molecular life sciences : CMLS · 2017Review
- A preliminary analysis of volatile metabolites of human induced pluripotent stem cells along the in vitro differentiation.Scientific reports · 2017Article
- Cardiomyocyte Differentiation Promotes Cell Survival During Nicotinamide Phosphoribosyltransferase Inhibition Through Increased Maintenance of Cellular Energy Stores.Stem cells translational medicine · 2017Article
- The Nexus of Stem Cell-Derived Beta-Cells and Genome Engineering.The review of diabetic studies : RDS · 2017Review
- Transgene Reactivation in Induced Pluripotent Stem Cell Derivatives and Reversion to Pluripotency of Induced Pluripotent Stem Cell-Derived Mesenchymal Stem Cells.Stem cells and development · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The tumorigenicity of human pluripotent stem cells (hPSCs) is widely acknowledged as a major obstacle that withholds their application in regenerative medicine. This protocol describes two efficient and robust ways to chemically eliminate the tumor-initiating hPSCs from monolayer culture. The protocol details how to maintain and differentiate hPSCs, how to apply chemical inhibitors to cultures of hPSCs and their differentiated progeny, and how to assess the purity of the resultant cell cultures using in vitro and in vivo assays. It also describes how to rescue the cytotoxic effect. The elimination and the rescue assay can be completed within 3-5 d, the in vitro assessment requires another day, and the in vivo assessment requires up to 12 additional weeks.
Indexed as
Identifiers
24577362What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.